



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: **AZD-7648**
CAS 号: **2230820-11-6**
产品货号: **S88606**

生物活性:

Description	AZD-7648 是一种具有选择性的口服有效 DNA-PK 抑制剂, IC50 值为 0.6 nM, AZD-7648 诱导细胞凋亡 (apoptosis), 具有抗肿瘤活性。			
IC50 & Target[1]	PI3Kγ 1.37 μM (IC50)	ATM 17.93 μM (IC50)	DNA-PKcs 91.3 nM (IC50)	
Cellular Effect	Cell Line	Type	Value	Description
	A549	IC50	0.091 μM	Inhibition of DNA-PK in human A549 cells assessed as reduction in irradiation-induced autophosphorylation at S2056 residue preincubated for 1 hr followed by 8 Gy irradiation and measured after 1 hr by ELISA
	B16-F10	IC50	11.4 μM	Synergistic antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs in presence of doxorubicin by CCK-8 assay
	B16-F10	IC50	33.6 μM	Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
	CHO	IC50	> 198 μM	Inhibition of human ERG stably expressed in CHO cells at -90 mV holding potential by electrophysiological assay
	CT26	IC50	18.8 μM	Antiproliferative activity against mouse CT26 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
	CT26	IC50	6.74 μM	Synergistic antiproliferative activity against mouse CT26 cells assessed as reduction in cell viability incubated for 48 hrs in presence of doxorubicin by CCK-8 assay
	HCT-116	IC50	19.5 μM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of 100 nM doxorubicin by MTT assay
	HCT-116	IC50	35.3 μM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
	HCT-116	IC50	38.08 nM	Inhibition of colony formation in human HCT-116 cells preincubated with compound for 1 hr followed by exposure to 2 Gy gamma irradiation and measured after 7 days by crystal violet staining based chemiluminescence assay
	HT-29	IC50	17.9 μM	Inhibition of ATM in human HT-29 cells assessed as reduction in irradiation-induced autophosphorylation at Ser1981 residue preincubated for 1 hr followed by 6 Gy irradiation and measured after 1 hr by Hoechst staining-based imaging analysis
	HT-29	IC50	> 29 μM	Inhibition of ATR in human HT-29 cells assessed as



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

				reduction in 4NQO-induced CHK1 phosphorylation at S345 residue preincubated for 1 hr followed by 4NQO addition and measured after 1 hr by Hoechst staining-based imaging analysis
	HeLa	IC ₅₀	0.6 nM	Inhibition of human HeLa cell-derived full length DNA-PK catalytic subunit using fluorescein-EPPLSQEAFADLWKK as substrate preincubated for 30 mins followed by substrate addition and measured after 40 mins TR-FRET assay
	Jurkat	IC ₅₀	0.09 μM	Synergistic antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs in presence of doxorubicin by CCK-8 assay
	Jurkat	IC ₅₀	12.3 μM	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
	MDA-MB-231	IC ₅₀	> 30 μM	Inhibition of mTOR/PI3Kalpha in human MDA-MB-231 cells assessed as reduction in AKT phosphorylation at S473 residue measured after 2 hrs by Hoechst staining-based imaging analysis
	MDA-MB-468	IC ₅₀	> 30 μM	Inhibition of PI3Kbeta in human MDA-MB-468 cells assessed as reduction in AKT phosphorylation at T208 residue measured after 2 hrs by QuantaBlu substrate based fluorescence assay
In Vitro	AZD7648 (0-30 μM) 是一种有效的放射增敏剂[1]。 AZD7648 (3 μM) 可增加对 Doxorubicin 的敏感性[1]。 AZD7648 (0.6 μM) 增强 PARP 抑制剂 Olaparib 的活性[1]。 Cell Cycle Analysis[1]			
	Cell Line:		IR (ionizing radiation)-treated A549 cells or A549 cells	
	Concentration:		0-30 μM	
	Incubation Time:		48 h	
	Result:		Arrested cell cycle at G2/M phase.	
	Western Blot Analysis[1]			
	Cell Line:		IR (ionizing radiation)-treated A549 cells or OAW42 cells treated with Doxorubicin	
	Concentration:		0.03, 0.1, 0.3, 1, 3, 10 and 30 μM for A549; 3 μM for OAW42	
	Incubation Time:		1 h for A549; 0.5, 2, 4, 8 and 16 h for OAW42	
	Result:		Potently inhibited DNA-PKcs autophosphorylation at Ser2056. Downregulated pDNA-PKcs Ser2056, γH2AX Ser139 and pRPA32 Ser4/Ser8 phosphorylation at early time points (at 30 min, 2 h and 4 h). Resulted in increased levels of γH2AX and the apoptosis marker cleaved PARP1 compared with doxorubicin treatment alone at later time points (8 and 16 h).	
In Vivo	AZD-7648（100 mg/kg; 口服; 每天一次, 连续 5 天）可抑制肿瘤生长并抑制肿瘤消退[1]。			



	<table><tr><td>Animal Model:</td><td>Nude mice, A549 xenografts and NCI-H1299 xenografts[1]</td></tr><tr><td>Dosage:</td><td>100 mg/kg</td></tr><tr><td>Administration:</td><td>Oral administration, once daily for 5 days</td></tr><tr><td>Result:</td><td>Induced tumour growth inhibition in combination with IR in A549 xenografts and induced tumour regression in combination with IR in NCI-H1299 xenografts.</td></tr></table>	Animal Model:	Nude mice, A549 xenografts and NCI-H1299 xenografts[1]	Dosage:	100 mg/kg	Administration:	Oral administration, once daily for 5 days	Result:	Induced tumour growth inhibition in combination with IR in A549 xenografts and induced tumour regression in combination with IR in NCI-H1299 xenografts.									
Animal Model:	Nude mice, A549 xenografts and NCI-H1299 xenografts[1]																	
Dosage:	100 mg/kg																	
Administration:	Oral administration, once daily for 5 days																	
Result:	Induced tumour growth inhibition in combination with IR in A549 xenografts and induced tumour regression in combination with IR in NCI-H1299 xenografts.																	
Solvent&Solubility	细胞实验: DMSO 中的溶解度 : 5.83 mg/mL (15.33 mM); 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响, 请使用新开封的 DMSO)																	
	<table><tr><td rowspan="4">Preparing Stock Solutions</td><td> SolventMassConcentration </td><td>1 mg</td><td>5 mg</td><td>10 mg</td></tr><tr><td>1 mM</td><td>2.6288 mL</td><td>13.1441 mL</td><td>26.2881 mL</td></tr><tr><td>5 mM</td><td>0.5258 mL</td><td>2.6288 mL</td><td>5.2576 mL</td></tr><tr><td>10 mM</td><td>0.2629 mL</td><td>1.3144 mL</td><td>2.6288 mL</td></tr></table>	Preparing Stock Solutions	SolventMassConcentration	1 mg	5 mg	10 mg	1 mM	2.6288 mL	13.1441 mL	26.2881 mL	5 mM	0.5258 mL	2.6288 mL	5.2576 mL	10 mM	0.2629 mL	1.3144 mL	2.6288 mL
	Preparing Stock Solutions		SolventMassConcentration	1 mg	5 mg	10 mg												
			1 mM	2.6288 mL	13.1441 mL	26.2881 mL												
			5 mM	0.5258 mL	2.6288 mL	5.2576 mL												
10 mM		0.2629 mL	1.3144 mL	2.6288 mL														
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。 动物实验: 以下溶解方案, 请直接配制工作液。建议现用现配, 在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶。 方案 一 请依序添加每种溶剂: 0.5% HPMC/0.1% Tween-80 in Saline water Solubility: 10 mg/mL (26.29 mM); 悬浊液; 超声助溶。																		
参考文献	[1]. Fok JHL, et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov 7;10(1):5065.																	
完整储备液配制表: 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80° C, 6 months; -20° C, 1 month。-80° C 储存时, 请在 6 个月内使用, -20° C 储存时, 请在 1 个月内使用。																		
可选溶剂	质量溶剂体积浓度	1 mg	5 mg	10 mg	25 mg													
DMSO	1 mM	2.6288 mL	13.1441 mL	26.2881 mL	65.7203 mL													
	5 mM	0.5258 mL	2.6288 mL	5.2576 mL	13.1441 mL													
	10 mM	0.2629 mL	1.3144 mL	2.6288 mL	6.5720 mL													
	15 mM	0.1753 mL	0.8763 mL	1.7525 mL	4.3814 mL													